Literature DB >> 7662489

Scintigraphic detection of recurrence of medullary thyroid cancer.

M Koizumi1, Y Yamada, E Nomura, M Amano, Y Okajima, H Okizuka, K Yamada, S Sawano, T Kitahara, T Yamashita.   

Abstract

A case of recurrent medullary thyroid cancer (MTC) was evaluated with 123I-MIBG, 99mTc(V)-dimercaptosuccinic acid (DMSA), and 201Tl scintigraphy. This patient had been operated on for MTC in the right thyroid. Recently a left neck mass was noticed, and was suspected of being a recurrence of MTC based on increased plasma calcitonin (CT) and carcinoembryonic antigen (CEA). He was operated on for the neck mass which revealed MTC, and papillary thyroid cancer was incidentally found in the left thyroid, but the CT and CEA levels remained high, and remaining MTC tumor was suspected. But the location of the tumor was unknown. Although 99mTc(V)-DMSA scintigraphy is generally believed to be superior in sensitivity to 123I-MIBG scintigraphy, it did not demonstrate the tumor site but 201Tl and 123I-MIBG did. Furthermore, 123I-MIBG scintigraphy has greater specificity for tumors which arise in the neural crest. Judging from the results of this case and cases reported in the literatures, both 123I-MIBG and 99mTc(V)-DMSA should be performed in the detection of recurrent MTC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662489     DOI: 10.1007/bf03164975

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  17 in total

1.  Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid.

Authors:  O A Mojiminiyi; R Udelsman; N D Soper; B J Shepstone; N E Dudley
Journal:  Clin Nucl Med       Date:  1991-04       Impact factor: 7.794

2.  Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma.

Authors:  C A Hoefnagel; C C Delprat; H R Marcuse; J J de Vijlder
Journal:  J Nucl Med       Date:  1986-12       Impact factor: 10.057

3.  The design of a pentavalent 99mTc-dimercaptosuccinate complex as a tumor imaging agent.

Authors:  A Yokoyama; N Hata; K Horiuchi; H Masuda; H Saji; H Ohta; K Yamamoto; K Endo; K Torizuka
Journal:  Int J Nucl Med Biol       Date:  1985

4.  New tracers for the imaging of the medullary thyroid carcinoma.

Authors:  U P Guerra; C Pizzocaro; A Terzi; R Giubbini; G Maira; R Pagliaini; M Bestagno
Journal:  Nucl Med Commun       Date:  1989-04       Impact factor: 1.690

5.  Sonography in the follow-up of 100 patients with thyroid carcinoma.

Authors:  J F Simeone; G H Daniels; D A Hall; K McCarthy; D B Kopans; R J Butch; P R Mueller; D D Stark; J T Ferrucci; C A Wang
Journal:  AJR Am J Roentgenol       Date:  1987-01       Impact factor: 3.959

6.  A new imaging agent for medullary carcinoma of the thyroid.

Authors:  H Ohta; K Yamamoto; K Endo; T Mori; D Hamanaka; A Shimazu; K Ikekubo; K Makimoto; Y Iida; J Konishi
Journal:  J Nucl Med       Date:  1984-03       Impact factor: 10.057

7.  Accumulation of thallium-201 in medullary thyroid cancer with negative serum calcitonin and carcinoembryonic antigens: a case report.

Authors:  M Koizumi; T Watari; K Hirabayashi
Journal:  Ann Nucl Med       Date:  1993-02       Impact factor: 2.668

8.  Radiotracer uptake in medullary carcinoma of the thyroid.

Authors:  K L Parthasarathy; K Shimaoka; S P Bakshi; M S Razack
Journal:  Clin Nucl Med       Date:  1980-02       Impact factor: 7.794

9.  Clinical evaluation of 99mTc(V)-dimercapto succinic acid (DMSA) for imaging medullary carcinoma of thyroid and its metastasis.

Authors:  M C Patel; R B Patel; P Ramanathan; N Ramamoorthy; B A Krishna; S M Sharma
Journal:  Eur J Nucl Med       Date:  1988

10.  Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study.

Authors:  J L Baulieu; D Guilloteau; M J Delisle; R Perdrisot; P Gardet; N Delépine; F Baulieu; J L Dupont; J N Talbot; G Coutris
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.